Web Content Viewer
Actions

Monoclonal Antibodies

Additional Dose COVID-19 Vaccine for those who are Immunocompromised 

 

According to the US Food and Drug Administration (FDA) and the CDC, a third dose of the mRNA COVID-19 vaccine can be administered to immunocompromised people following completion of the two-dose COVID-19 vaccine series. 

  • People with moderately to severely compromised immune systems are especially vulnerable to COVID-19, and may not build the same level of immunity to 2-dose vaccine series compared to people who are not immunocompromised.
  • This additional dose is intended to improve immunocompromised people’s response to their initial vaccine series.

 

Who’s eligible for an additional dose of COVID-19 vaccine? 

The third dose is recommended at least 28 days following completion of the second dose for qualifying immunocompromised people ages 12 and older who have received the Pfizer (Comirnaty) series and people ages 18 and older who have received the Moderna series. At this time, an additional dose is not recommended after the single-dose Johnson & Johnson (Janssen) vaccine.  

The CDC has defined eligibility for an additional vaccine dose, which includes people with moderate or severe immunocompromising conditions, such as those: 

  • undergoing treatment for cancer, 
  • who have received a solid organ transplant, 
  • who have received a bone marrow transplant, 
  • who have received CAR T-cell therapy, 
  • with primary immunodeficiency, 
  • with advanced or untreated HIV/AIDS, 
  • and undergoing treatment with immunosuppressive or immunomodulatory medications, including high-dose corticosteroids (≥ 20 mg prednisone per day for ≥ 14 days). 

 

Do patients need to get the same vaccine as their first doses? 

It is strongly encouraged that patients receive the same vaccine that was administered for the first two doses. Both Pfizer (Comirnaty) and Moderna are available in Ohio. If one is unavailable, the other vaccine may be administered.